Treated animals show significant improvements in body composition without changes in food intake
Thymosin Beta-4 and its derivatives, including TB-500, are listed under section S2.3 (Growth Factors and Growth Factor Modulators) as a non-Specified Substance, prohibited at all times in and out of competition
Similarly, the 28-day or 56-day windows for brand-name products are hard limits
Rest alone rarely resolves underlying tissue damage
They should remain separated from the main dosing protocol because the FDA review specifically flagged the absence of published human exposure data for subcutaneous, transdermal, and intranasal routes
It belongs in a comparison page where the details that matter most are access, cost, clinical fit, and what a licensed clinician should confirm